Abstract
This update covers the period March 2013, with information sourced from company press releases, regulatory and patent agencies. This month saw approvals for therapeutics featuring drug-delivery technologies: Biogen Idec’s first-line oral multiple sclerosis drug Tecfidera™ and Novartis’ TOBI Podhaler™ for cystic fibrosis. Titan Pharmaceutical received positive news from the US FDA advisory board regarding its product for the maintenance treatment of adult patients with opioid dependence, Probuphine®. On the merger and acquisitions front, AstraZeneca paid a staggering US$240 million upfront to gain access to Moderna’s early-stage mRNA technology. Shire acquired Swedish company Premacure allowing it access to the neonatal therapeutic area.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
